Mode
Text Size
Log in / Sign up

Nasopharyngeal swab tNGS shows high bacterial concordance with BALF in ICU pneumoniaNasal swabs can spot key pneumonia germs in ICU patients when lung tests aren't ready

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider NPS tNGS as an adjunct for bacterial detection in ICU pneumonia, but recognize BALF remains essential for comprehensive assessment.

This was a prospective observational cohort study in 105 critically ill and immunocompromised patients with severe pneumonia in the ICU. The intervention was paired nasopharyngeal swabs (NPS) and bronchoalveolar lavage fluid (BALF) sampling with targeted next-generation sequencing (tNGS), using BALF as the reference standard for pathogen detection.

For major bacterial pathogens (Acinetobacter baumannii, Staphylococcus aureus, Escherichia coli), concordance between NPS and BALF was high, with positive percent agreement (PPA) ≥ 80.0% and overall detection rates ≥ 90.0%. Viral detection sensitivity was moderate, with PPA ≤ 80.0%. Fungal concordance was variable, ranging from 0.0% for Aspergillus flavus to 50.0% for Pneumocystis jirovecii.

Longitudinal monitoring of pathogen changes was performed in 74 patients and showed limited utility, with higher agreement only for Staphylococcus aureus (72.7%), Acinetobacter baumannii (62.5%), and fungal pathogens (75.0%). Safety data were not reported.

Key limitations include reduced sensitivity for fungal and viral pathogens, limited performance in longitudinal surveillance, and the need for BALF for comprehensive infection assessment. The practice relevance is that NPS-based tNGS may support early antimicrobial decision-making when BALF is not immediately available, but BALF is still needed, especially in immunocompromised and high-risk ICU populations. This is an observational study; association only, no causation inferred.

When someone is fighting severe pneumonia in the ICU, doctors need to know exactly which germ is causing it to choose the right treatment. This study tested whether a simple nasal swab could match the more invasive lung fluid test for finding those germs.

Researchers compared nasal swabs to lung fluid samples from 105 critically ill and immunocompromised patients. They found high agreement for major bacterial threats like Acinetobacter and Staphylococcus, with the nasal swab correctly identifying them over 80% of the time. However, the swab was less reliable for viruses and fungi, and its usefulness for tracking germ changes over time was limited.

The study shows that a nasal swab can be a helpful early tool when a lung test isn't immediately available, but it doesn't replace the lung fluid test for a complete picture. This is especially important for high-risk ICU patients who need precise answers.

The main caveat is that this was an observational study, so it shows an association, not a cause-and-effect proof. The sample size was modest, and the results for viruses and fungi were weaker, meaning the lung test remains essential for a full assessment.

What this means for you:
Nasal swabs can help spot key pneumonia bacteria fast, but lung tests are still needed for a full diagnosis.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundDrug-resistant bacterial and fungal infections represent a major cause of morbidity and mortality among critically ill and immunocompromised patients with severe pneumonia. Molecular diagnostics using bronchoalveolar lavage fluid (BALF) are considered the reference standard for pathogen identification but are invasive and often contraindicated in unstable intensive care unit (ICU) patients. Safer non-invasive sampling strategies that maintain diagnostic reliabilityfor clinically relevant and potentially drug-resistant pathogens are therefore urgently needed.MethodsIn this prospective cohort study conducted between January 1 and July 30, 2024, paired nasopharyngeal swabs (NPS) and BALF samples were collected from 105 ICU patients with severe pneumonia. Pathogen detection was performed using targeted next-generation sequencing (tNGS) with a focus on clinically significant bacterial, viral, and fungal pathogens commonly associated with antimicrobial resistance. Concordance between NPS and BALF was evaluated using positive percent agreement (PPA) and negative percent agreement (NPA), with BALF serving as the reference standard. Longitudinal two-phase sampling was performed in 74 patients to assess the capacity of NPS to monitor temporal changes in pathogen profiles.ResultsCompared with BALF, NPS demonstrated high concordance for major bacterial pathogens frequently associated with drug resistance, including Acinetobacter baumannii, Staphylococcus aureus, and Escherichia coli, with PPA ≥ 80.0% and overall detection rates ≥90.0%. NPA exceeded 95.0% for most pathogens, indicating a low false-positive rate. Viral detection showed moderate sensitivity (PPA ≤ 80.0%), while fungal concordance was variable, ranging from 0.0% for Aspergillus flavus to 50.0% for Pneumocystis jirovecii. Longitudinal analyses revealed limited utility of NPS for monitoring dynamic pathogen changes over time, with higher agreement observed only for Staphylococcus aureus (72.7%), Acinetobacter baumannii (62.5%), and fungal pathogens (75.0%).ConclusionNasopharyngeal swab–based tNGS represents a feasible and less invasive approach for the early molecular identification of common bacterial pathogens, including those frequently implicated in drug-resistant infections, in patients with severe ICU pneumonia. While NPS may support early antimicrobial decision-making when BALF is not immediately available, its reduced sensitivity for fungal and viral pathogens and limited performance in longitudinal surveillance underscore the continued necessity of BALF for comprehensive infection assessment, particularly in immunocompromised and high-risk ICU populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.